Arcus Biosciences
RCUS
130 hedge funds and large institutions have $1.24B invested in Arcus Biosciences in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 45 increasing their positions, 46 reducing their positions, and 32 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
0.5% more ownership
Funds ownership: 63.12% → 63.62% (+0.5%)
1% less capital invested
Capital invested by funds: $1.25B → $1.24B (-$17.4M)
2% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 46
12% less funds holding
Funds holding: 148 → 130 (-18)
38% less call options, than puts
Call options by funds: $7.63M | Put options by funds: $12.3M
56% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 32
Top Buyers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$32.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$26.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.5M |
| 4 |
BlackRock
New York
|
+$18.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14.9M |
Top Sellers
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$41.7M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$30.6M |
| 3 |
HM
HealthCor Management
New York
|
-$15.1M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$10.2M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$6.64M |
RCUS Hedge Fund Activity: Q2 2021 in Review
130 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2021, worth a combined $1.24B — down 1.4% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of RCUS and 14 opened new positions — a net loss of 18 holders — while 46 trimmed existing stakes and 45 added.
The largest buyer was EcoR1 Capital, adding an estimated $32.5M. The largest seller was Victory Capital Management, cutting an estimated $41.7M.
- 130 institutional investors held Arcus Biosciences (RCUS) as of Q2 2021, down from 148 in Q1 2021.
- Funds reported $1.24B of Arcus Biosciences stock for Q2 2021, down 1.4% quarter-over-quarter.
- 14 funds opened new Arcus Biosciences positions in Q2 2021 and 32 closed out, a net change of -18 holders.
- The largest Arcus Biosciences buyer in Q2 2021 was EcoR1 Capital, an estimated $32.5M added.
- The largest Arcus Biosciences seller in Q2 2021 was Victory Capital Management, an estimated $41.7M sold.
Based on aggregated 13F filings for Q2 2021.